-
Something wrong with this record ?
Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats
Alexandra Sporková, Libor Kopkan, Šárka Varcabová, Zuzana Husková, Sung Hee Hwang, Bruce D. Hammock, John D. Imig, Herbert J. Kramer, Luděk Červenka
Language English Country United States
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Grant support
NS9699
MZ0
CEP Register
NS10499
MZ0
CEP Register
Digital library NLK
Full text - Article
Full text - Article
Source
Source
NLK
Open Access Digital Library
from 1997-10-01
- MeSH
- Amidines pharmacology MeSH
- Epoxide Hydrolases antagonists & inhibitors MeSH
- Enzyme Inhibitors pharmacology MeSH
- Blood Pressure drug effects physiology MeSH
- Rats MeSH
- Arachidonic Acids metabolism MeSH
- Hydroxyeicosatetraenoic Acids metabolism MeSH
- Kidney blood supply drug effects physiology MeSH
- Disease Models, Animal MeSH
- Regional Blood Flow drug effects MeSH
- Hypertension, Renovascular metabolism physiopathology MeSH
- Sodium urine MeSH
- Cytochrome P-450 Enzyme System metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
Alterations in renal function contribute to Goldblatt two-kidney, one-clip (2K1C) hypertension. A previous study indicated that bioavailability of cytochrome P-450 metabolites epoxyeicosatrienoic acids (EETs) is decreased while that of 20-hydroxyeicosatetraenoic acids (20-HETE) is increased in this model. We utilized the inhibitor of soluble epoxide hydrolase cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (c-AUCB) and HET-0016, the inhibitor of 20-HETE production, to study the role of EETs and 20-HETE in the regulation of renal function. Chronic c-AUCB treatment significantly decreased systolic blood pressure (SBP) (133 ± 1 vs. 163 ± 3 mmHg) and increased sodium excretion (1.23 ± 0.10 vs. 0.59 ± 0.03 mmol/day) in 2K1C rats. HET-0016 did not affect SBP and sodium excretion. In acute experiments, renal blood flow (RBF) was decreased in 2K1C rats (5.0 ± 0.2 vs. 6.9 ± 0.2 ml·min(-1)·g(-1)). c-AUCB normalized RBF in 2K1C rats (6.5 ± 0.6 ml·min(-1)·g(-1)). HET-0016 also increased RBF in 2K1C rats (5.8 ± 0.2 ml·min(-1)·g(-1)). Although RBF and glomerular filtration rate (GFR) remained stable in normotensive rats during renal arterial pressure (RAP) reductions, both were significantly reduced at 100 mmHg RAP in 2K1C rats. c-AUCB did not improve autoregulation but increased RBF at all RAPs and shifted the pressure-natriuresis curve to the left. HET-0016-treated 2K1C rats exhibited impaired autoregulation of RBF and GFR. Our data indicate that c-AUCB displays antihypertensive properties in 2K1C hypertension that are mediated by an improvement of RBF and pressure natriuresis. While HET-0016 enhanced RBF, its anti-natriuretic effect likely prevented it from producing a blood pressure-lowering effect in the 2K1C model.
Center for Cardiovascular Research Prague
Department of Pharmacology and Toxicology Medical College of Wisconsin Milwaukee Wisconsin
Department of Physiology 2nd Medical Faculty Charles University Prague Czech Republic
Section of Nephrology Medical Policlinic Department of Medicine University of Bonn Bonn Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027710
- 003
- CZ-PrNML
- 005
- 20170411101952.0
- 007
- ta
- 008
- 120817s2011 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1152/ajpregu.00215.2010 $2 doi
- 035 __
- $a (PubMed)21411763
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Sporková, Alexandra $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague. alhc@ikem.cz
- 245 10
- $a Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats / $c Alexandra Sporková, Libor Kopkan, Šárka Varcabová, Zuzana Husková, Sung Hee Hwang, Bruce D. Hammock, John D. Imig, Herbert J. Kramer, Luděk Červenka
- 520 9_
- $a Alterations in renal function contribute to Goldblatt two-kidney, one-clip (2K1C) hypertension. A previous study indicated that bioavailability of cytochrome P-450 metabolites epoxyeicosatrienoic acids (EETs) is decreased while that of 20-hydroxyeicosatetraenoic acids (20-HETE) is increased in this model. We utilized the inhibitor of soluble epoxide hydrolase cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (c-AUCB) and HET-0016, the inhibitor of 20-HETE production, to study the role of EETs and 20-HETE in the regulation of renal function. Chronic c-AUCB treatment significantly decreased systolic blood pressure (SBP) (133 ± 1 vs. 163 ± 3 mmHg) and increased sodium excretion (1.23 ± 0.10 vs. 0.59 ± 0.03 mmol/day) in 2K1C rats. HET-0016 did not affect SBP and sodium excretion. In acute experiments, renal blood flow (RBF) was decreased in 2K1C rats (5.0 ± 0.2 vs. 6.9 ± 0.2 ml·min(-1)·g(-1)). c-AUCB normalized RBF in 2K1C rats (6.5 ± 0.6 ml·min(-1)·g(-1)). HET-0016 also increased RBF in 2K1C rats (5.8 ± 0.2 ml·min(-1)·g(-1)). Although RBF and glomerular filtration rate (GFR) remained stable in normotensive rats during renal arterial pressure (RAP) reductions, both were significantly reduced at 100 mmHg RAP in 2K1C rats. c-AUCB did not improve autoregulation but increased RBF at all RAPs and shifted the pressure-natriuresis curve to the left. HET-0016-treated 2K1C rats exhibited impaired autoregulation of RBF and GFR. Our data indicate that c-AUCB displays antihypertensive properties in 2K1C hypertension that are mediated by an improvement of RBF and pressure natriuresis. While HET-0016 enhanced RBF, its anti-natriuretic effect likely prevented it from producing a blood pressure-lowering effect in the 2K1C model.
- 650 _2
- $a amidiny $x farmakologie $7 D000578
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kyseliny arachidonové $x metabolismus $7 D001095
- 650 _2
- $a krevní tlak $x účinky léků $x fyziologie $7 D001794
- 650 _2
- $a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a inhibitory enzymů $x farmakologie $7 D004791
- 650 _2
- $a epoxid hydrolasy $x antagonisté a inhibitory $7 D004851
- 650 _2
- $a kyseliny hydroxyeikosatetraenové $x metabolismus $7 D006893
- 650 _2
- $a renovaskulární hypertenze $x metabolismus $x patofyziologie $7 D006978
- 650 _2
- $a ledviny $x krevní zásobení $x účinky léků $x fyziologie $7 D007668
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a regionální krevní průtok $x účinky léků $7 D012039
- 650 _2
- $a sodík $x moč $7 D012964
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kopkan, Libor $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague
- 700 1_
- $a Varcabová, Šárka $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague
- 700 1_
- $a Husková, Zuzana $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague
- 700 1_
- $a Hwang, Sung Hee $u Department of Entomology and University of California Davis Cancer Center, University of California, Davis, California
- 700 1_
- $a Hammock, Bruce D. $u Department of Entomology and University of California Davis Cancer Center, University of California, Davis, California
- 700 1_
- $a Imig, John D. $u Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin
- 700 1_
- $a Kramer, Herbert J. $u Section of Nephrology, Medical Policlinic, Department of Medicine, University of Bonn, Bonn, Germany
- 700 1_
- $a Červenka, Luděk $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Physiology, 2nd Medical Faculty, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00006004 $t American journal of physiology. Regulatory, integrative and comparative physiology $x 1522-1490 $g Roč. 300, č. 6 (2011), s. R1468-R1475
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21411763 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20170411102251 $b ABA008
- 999 __
- $a ok $b bmc $g 949752 $s 785056
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 300 $c 6 $d R1468-R1475 $e 20110316 $i 1522-1490 $m American journal of physiology. Regulatory, integrative and comparative physiology $n Am J Physiol Regul Integr Comp Physiol $x MED00006004
- GRA __
- $a NS9699 $p MZ0
- GRA __
- $a NS10499 $p MZ0
- LZP __
- $a Pubmed-20120817/11/03
